The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK, July 1, 2021 /PRNewswire/ — ObvioHealth, a global Virtual Research Organization (VRO), announces it […]
In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.
Jerusalem-based SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. Participating in the round were OrbiMed, Israel Biotech Fund, Integra Holdings and the Cystic Fibrosis Foundation.
2021 is shaping up to be another banner year for biotech companies. According to BioSpace, funds appear to be in near-endless supply as companies advance next-gen technologies and therapeutics for the health of all. BioSpace reviews a few raking in cash for their programs.
After filing plans for an initial public offering earlier in April, U.K.-based Vaccitech raised $110.5 million in the company’s IPO and on April 30 announced the pricing of 6.5 million American Depositary Shares at $17 per share.
Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.
Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s Covid-19 vaccine, raised $168 million in a Series B financing round that will be used to support development of its own lead candidates in oncology and infectious disease.
LightDeck Diagnostics was awarded a $5.65 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services (HHS), to develop an rapid antigen test to detect SARS-CoV-2.
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
